VEGF-VEGF receptor complexes as markers of tumor vascular endothelium

R. A. Brekken, P. E. Thorpe

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) is a primary stimulant of the vascularization of solid tumors and has therefore been the focus of intense research aimed at blocking its activity in solid tumors. VEGF production by tumor cells is induced by oncogenic gene mutations and hypoxic conditions inside the tumor mass. VEGF receptor expression on endothelial cells lining blood vessels in the tumor is also induced by hypoxia and the increased local concentration of VEGF. Therefore in the tumor microenvironment there is an upregulation of both VEGF and its receptor leading to a high concentration of occupied receptor on tumor vascular endothelium. The VEGF-VEGF receptor complex (VEGF-VEGFR) presents an attractive target for the specific delivery of drugs or other effectors to tumor endothelium. Herein we review the development of monoclonal antibodies that selectively bind to the VEGF-VEGFR and their use as targeting agents that selectively bind to VEGF activated blood vessels. Additionally, we summarize the properties of 2C3, a novel monoclonal anti-VEGF antibody that blocks VEGF from binding to VEGFR2 but not VEGFR1. 2C3 may be utilized as both an anti-angiogenic agent by inhibiting VEGFR2 activity and potentially as a vascular targeting agent by binding to blood vessels that express the VEGF-VEGFR1 complex.

Original languageEnglish (US)
Pages (from-to)173-181
Number of pages9
JournalJournal of Controlled Release
Volume74
Issue number1-3
DOIs
StatePublished - Jul 6 2001

Fingerprint

Vascular Endothelial Growth Factor Receptor
Vascular Endothelium
Tumor Biomarkers
Vascular Endothelial Growth Factor A
Blood Vessels
Neoplasms
Vascular Tissue Neoplasms
Tumor Microenvironment
Endothelium
Up-Regulation
Endothelial Cells
Monoclonal Antibodies
Mutation
Antibodies

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. / Brekken, R. A.; Thorpe, P. E.

In: Journal of Controlled Release, Vol. 74, No. 1-3, 06.07.2001, p. 173-181.

Research output: Contribution to journalArticle

@article{ca90469e21e74640b6c154422cac65a1,
title = "VEGF-VEGF receptor complexes as markers of tumor vascular endothelium",
abstract = "Vascular endothelial growth factor (VEGF) is a primary stimulant of the vascularization of solid tumors and has therefore been the focus of intense research aimed at blocking its activity in solid tumors. VEGF production by tumor cells is induced by oncogenic gene mutations and hypoxic conditions inside the tumor mass. VEGF receptor expression on endothelial cells lining blood vessels in the tumor is also induced by hypoxia and the increased local concentration of VEGF. Therefore in the tumor microenvironment there is an upregulation of both VEGF and its receptor leading to a high concentration of occupied receptor on tumor vascular endothelium. The VEGF-VEGF receptor complex (VEGF-VEGFR) presents an attractive target for the specific delivery of drugs or other effectors to tumor endothelium. Herein we review the development of monoclonal antibodies that selectively bind to the VEGF-VEGFR and their use as targeting agents that selectively bind to VEGF activated blood vessels. Additionally, we summarize the properties of 2C3, a novel monoclonal anti-VEGF antibody that blocks VEGF from binding to VEGFR2 but not VEGFR1. 2C3 may be utilized as both an anti-angiogenic agent by inhibiting VEGFR2 activity and potentially as a vascular targeting agent by binding to blood vessels that express the VEGF-VEGFR1 complex.",
author = "Brekken, {R. A.} and Thorpe, {P. E.}",
year = "2001",
month = "7",
day = "6",
doi = "10.1016/S0168-3659(01)00333-9",
language = "English (US)",
volume = "74",
pages = "173--181",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - VEGF-VEGF receptor complexes as markers of tumor vascular endothelium

AU - Brekken, R. A.

AU - Thorpe, P. E.

PY - 2001/7/6

Y1 - 2001/7/6

N2 - Vascular endothelial growth factor (VEGF) is a primary stimulant of the vascularization of solid tumors and has therefore been the focus of intense research aimed at blocking its activity in solid tumors. VEGF production by tumor cells is induced by oncogenic gene mutations and hypoxic conditions inside the tumor mass. VEGF receptor expression on endothelial cells lining blood vessels in the tumor is also induced by hypoxia and the increased local concentration of VEGF. Therefore in the tumor microenvironment there is an upregulation of both VEGF and its receptor leading to a high concentration of occupied receptor on tumor vascular endothelium. The VEGF-VEGF receptor complex (VEGF-VEGFR) presents an attractive target for the specific delivery of drugs or other effectors to tumor endothelium. Herein we review the development of monoclonal antibodies that selectively bind to the VEGF-VEGFR and their use as targeting agents that selectively bind to VEGF activated blood vessels. Additionally, we summarize the properties of 2C3, a novel monoclonal anti-VEGF antibody that blocks VEGF from binding to VEGFR2 but not VEGFR1. 2C3 may be utilized as both an anti-angiogenic agent by inhibiting VEGFR2 activity and potentially as a vascular targeting agent by binding to blood vessels that express the VEGF-VEGFR1 complex.

AB - Vascular endothelial growth factor (VEGF) is a primary stimulant of the vascularization of solid tumors and has therefore been the focus of intense research aimed at blocking its activity in solid tumors. VEGF production by tumor cells is induced by oncogenic gene mutations and hypoxic conditions inside the tumor mass. VEGF receptor expression on endothelial cells lining blood vessels in the tumor is also induced by hypoxia and the increased local concentration of VEGF. Therefore in the tumor microenvironment there is an upregulation of both VEGF and its receptor leading to a high concentration of occupied receptor on tumor vascular endothelium. The VEGF-VEGF receptor complex (VEGF-VEGFR) presents an attractive target for the specific delivery of drugs or other effectors to tumor endothelium. Herein we review the development of monoclonal antibodies that selectively bind to the VEGF-VEGFR and their use as targeting agents that selectively bind to VEGF activated blood vessels. Additionally, we summarize the properties of 2C3, a novel monoclonal anti-VEGF antibody that blocks VEGF from binding to VEGFR2 but not VEGFR1. 2C3 may be utilized as both an anti-angiogenic agent by inhibiting VEGFR2 activity and potentially as a vascular targeting agent by binding to blood vessels that express the VEGF-VEGFR1 complex.

UR - http://www.scopus.com/inward/record.url?scp=0035816194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035816194&partnerID=8YFLogxK

U2 - 10.1016/S0168-3659(01)00333-9

DO - 10.1016/S0168-3659(01)00333-9

M3 - Article

C2 - 11489493

AN - SCOPUS:0035816194

VL - 74

SP - 173

EP - 181

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1-3

ER -